Amarin is a clinical-stage biopharmaceutical company with a focus on cardiovascular disease. The Company’s lead product candidate is AMR101, a prescription grade Omega-3 product comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Amarin also has next-generation lipid candidates under evaluation for preclinical development. Amarin recently established its research and development headquarters in Mystic, Connecticut with an experienced research and development team. Amarin’s programs capitalize on its lipid science expertise and the known therapeutic benefits of Omega-3 products in treating cardiovascular disease. Amarin has a number of non-core programs for partnering in the area of central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease.
Company Growth (employees)
Dublin, IE
Size (employees)
210 (est)
Amarin was founded in 1991 and is headquartered in Dublin, IE

Key People at Amarin

Colin Stewart

Colin Stewart

President and CEO
Joseph S. Zakrzewski

Joseph S. Zakrzewski

Executive Chairman and Chief Executive Officer
John Thero

John Thero

Declan Doogan

Declan Doogan

Chief Medical Officer

Amarin Office Locations

Amarin has offices in Dublin, Bedminster Township
Dublin, IE (HQ)
Pembroke House Pembroke Street Upper
Bedminster Township, US
1430 US-206

Amarin Metrics

Amarin Financial Metrics

Revenue (2016)

$130.1 m

Revenue growth (2015-16), %


Gross profit

$95.7 m

Gross profit margin (2016), %


Net income (2016)

($86.4 m)

Market capitalization (21-Mar-2017)

$895.1 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$98.3 m
Amarin's current market capitalization is $895.1 m.
Amarin's revenue was reported to be $130.1 m in FY, 2016 which is a 59.1% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$26.4 m$54.2 m$81.8 m$130.1 m

Revenue growth, %


Cost of goods sold

$11.9 m$20.5 m$27.9 m$34.4 m

Gross profit

$14.4 m$33.7 m$53.9 m$95.7 m

Gross profit Margin, %


R&D expense

$72.8 m$50.3 m$51.1 m$50 m

General and administrative expense

$123.8 m$79.3 m$101 m$111.4 m

Operating expense total

$208.5 m$129.7 m$152.1 m$161.3 m


($182.1 m)($96 m)($98.2 m)($65.6 m)

EBIT margin, %


Interest expense

$34.2 m$18.6 m$20.2 m$18.7 m

Interest income

$343 k$96 k$132 k$234 k

Pre tax profit

($169.4 m)($59.2 m)($118.3 m)($76.4 m)

Income tax expense

$3.2 m$2.8 m$3.1 m($10 m)

Net Income

($166.2 m)($56.4 m)($115.2 m)($86.4 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$191.5 m$119.5 m$107 m$98.3 m

Accounts Receivable

$3.6 m$7.8 m$13.8 m$20 m


$19 m$20.5 m

Current Assets

$219.4 m$145.3 m$143.5 m$146.3 m


$579 k$381 k$243 k$78 k

Total Assets

$252.5 m$171.1 m$173.5 m$167 m

Accounts Payable

$6.4 m$8.5 m$10.8 m$6.1 m

Total Debt

$105 m$106.3 m

Current Liabilities

$37.5 m$40.3 m$50.7 m$76.2 m

Additional Paid-in Capital

$738.8 m$738.9 m$816.2 m$964.9 m

Retained Earnings

($913.9 m)($970.2 m)($1.1 b)($1.2 b)

Total Equity

($33.9 m)($88.4 m)($129.2 m)($9.1 m)

Debt to Equity Ratio

-1.2 x-0.8 x

Debt to Assets Ratio

0.6 x0.6 x

Financial Leverage

-7.5 x-1.9 x-1.3 x-18.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($166.2 m)($56.4 m)($115.2 m)($86.4 m)

Depreciation and Amortization

$246 k$198 k$166 k$138 k

Accounts Receivable

($3.6 m)($4.2 m)($6 m)($6.2 m)


($5.4 m)$13 m($5.3 m)($1.5 m)

Accounts Payable

$10.5 m$2.4 m($652 k)($6.2 m)

Cash From Operating Activities

($190.3 m)($72.3 m)($84.7 m)($71.8 m)

Cash From Investing Activities

($14 k)($14 k)($28 k)($21 k)

Cash From Financing Activities

$121.6 m$334 k$72.2 m$63.1 m

Interest Paid

$6.1 m$10 m$12.6 m$17.1 m

Income Taxes Paid

$1.4 m$781 k$711 k$1.5 m

Amarin Market Value History

Amarin Company Life

You may also be interested in